Objective: Synovial sarcoma displays a wide clinicopathological spectrum and a specific translocation t(X; 18)(SYT-SSX)(p11.2; q11.2). Cost constraints limit molecular confirmation in every case. Lately, TLE1 has been recognized as a useful IHC marker. Herein, we present IHC review of 42 synovial sarcomas, including TLE1 expression. Method: Forty-two synovial sarcomas included monophasic spindle-cell type (26) (61.9 %), biphasic 13 (30.9 %), calcifying (2) (4.7 %) and poorly-differentiated type (1) (2.3 %). 21 tumors were confirmed with molecular analysis. TLE1 immunostaining was graded from 0, 1+, 2+, 3+, with 2+ or 3+ grades interpreted as positive staining. Results: On IHC, various synovial sarcomas were positive for EMA (26/34)(76.4 %), CK7 (6/10) (60 %), CK/MNF116 (6/21)(28.6 %), BCL2 (36/37)(97.3 %), MIC2 (23/ 31)(74.1 %) and TLE1 (40/42)(95.2 %), while negative for CD34 (0/21). Among 70 other tumors, TLE1 was positive in schwannomas (5/5) (100 %), neurofibromas (2/2)(100 %), MPNSTs (2/12)(17 %) and PNETs (4/10)(40 %). Sensitivity and specificity of TLE1 for synovial sarcoma was 95.2 % and 72 %. 50 % of PNST (75 % of schwanomas, 50 % of MPNST and 25 % of neurofibromas). In contrast, HER3 positivity was observed in 20 % of other mesenchymal tumors (28 % uterine and 9 % non-uterine leiomiomas, 18 % uterine and 25 % nonuterine leiomiosarcomas, 29 % UPS). Conclusion: HER3 overexpression is frequently found in PNST, including 50 % of MPNST. Due to the crucial role of HER3 receptor in cell signalling as a main activator of the PI3K pathway, these results support the rationale of developing new therapeutic approaches in MPNST. Objective: Nonneural granular cell tumour (NNGCT) is a rare neoplasm described in 1991 by Leboit et al. Till now, no more than 35 cases have been presented in the literature, nearly all were limited to the skin. We report the first NNGCT of the breast and present its morphological and immunohistochemical characteristics. Method: A 39 year-old female underwent lumpectomy because of tumour of the breast. After routine histological examination, the immunohistochemical studies were performed using commercially available antibodies against cytokeratins (AE1/AE3), CD68, CD1A, S100, CD34, smooth muscle actin, desmin, miogenin, inhibin, and Ki67 antigen (MiB1). Results: Microscopically, the tumour was composed of ovoid and polygonal cells with abundant granular, eosinophilic cytoplasm. The cells presented mild or moderate polymorphism and trace mitotic activity. They were arranged in diffuse sheets with no evidence of nesting or fasciculation. The histological texture of the tumour resembled that of classical granular cell tumour of Abrikosoff. However, the tumour cells were strongly immunoreactive for CD68 and inhibin, whereas the reactions against S100 protein as well as other antigens studied gave negative results. The value of Ki67 index did not exceed 2-3 %. Conclusion: The differential diagnosis of granular cell myoblastoma (Abrikossoff tumour) should include the nonneural granular cell tumour.